BEIZRAY Trademark

Trademark Overview


On Tuesday, September 12, 2023, a trademark application was filed for BEIZRAY with the United States Patent and Trademark Office. The USPTO has given the BEIZRAY trademark a serial number of 98176852. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, July 2, 2024. This trademark is owned by Zhuhai Beihai Biotech Co., Ltd.. The BEIZRAY trademark is filed in the Pharmaceutical Products category with the following description:

Analgesics; Antiemetics; Biological preparations for the treatment of cancer; Blood substitute for human use; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of cancer; Chemical reagents for medical purposes; Medicinal infusions for treating cancer; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicines made of Chinese traditional medicinal herbs; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the treatment of cancer; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders
beizray

General Information


Serial Number98176852
Word MarkBEIZRAY
Filing DateTuesday, September 12, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, July 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements


Goods and ServicesAnalgesics; Antiemetics; Biological preparations for the treatment of cancer; Blood substitute for human use; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of cancer; Chemical reagents for medical purposes; Medicinal infusions for treating cancer; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicines made of Chinese traditional medicinal herbs; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the treatment of cancer; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 12, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameZhuhai Beihai Biotech Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressZhuhai, Guangdong 519090
CN

Party NameZhuhai Beihai Biotech Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressZhuhai, Guangdong 519090
CN

Trademark Events


Event DateEvent Description
Wednesday, September 13, 2023NEW APPLICATION ENTERED
Sunday, November 26, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 14, 2024ASSIGNED TO EXAMINER
Thursday, March 21, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, March 21, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, March 21, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, March 21, 2024EXAMINER'S AMENDMENT ENTERED
Monday, April 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED